For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Take a look at our BETA site and see what we’ve done so far.
Search and browse selected products
Purchase these through your usual distributor
Published 13 May, 2022
PD-L1 is a widely used biomarker that is often quantified by IHC, in addition to forming the basis of a new class of immunotherapy. Our development scientists recognized the need for a suite of class-leading tools for this important biomarker and spearheaded the mission to create high-quality reagents including knock-out cell lines, recombinant antibodies, and immunoassays.
Whether you are using biomarkers as a therapeutic target or as a diagnostic tool, our scientists know that having confidence in all your reagents is critical. That’s why our quality mission drives us to create innovative tools that let you generate high-quality, reproducible data right from the first experiment.
Browse our biomarker resources to find the solutions that could help advance your discovery:
|Implementation of the FirePlex multiplexed immunoassay for discovery of neuroinflammatory biomarkers||Dr Lauren Martens has a passion for identifying ways to intervene in CNS diseases, and, as the scientific co-founder of Tiaki Therapeutics, she co-leads the first DDF Discovery project focused on neuroinflammation. Here, she explains how using FirePlex assay technology helps them to identify potential biomarkers.|
|Insights into how biomarker profiling can be successfully applied in drug discovery and clinical applications|
Michael Tackett, our Director of Assay Services, is driven to minimize workloads and increase efficiency in laboratory and clinical assays. In this webinar, he examines real-world case studies to demonstrate how multiplexing can scale up biomarker quantification.
|Enabling biomarker discovery and screening with firePlex multiplexed assays|
Dr Paul Wylie, Director of Multiplex at Abcam, is focused on delivering high-throughput solutions for drug discovery. In this webinar, he discusses how FirePlex immunoassays can improve efficiency in biomarker discovery and screening.
Guides and technical notes
|Tools for immuno-oncology biomarker research||To fully unleash the power of immuno-oncology, new and improved biomarkers are needed that can accurately predict therapeutic responses. Here we highlight some of our most popular immuno-oncology antibodies to support your research.|
|Cancer biomarkers guide||IHC is the gold standard in clinical cancer diagnostics, so we are determined to deliver sensitive and specific antibodies against key biomarkers. Our cancer biomarker guide will help you to select the best antibody for your research.|